![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 5, 3342-3349, February 1, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
B for Chromium(VI)-induced Cytotoxicity
Is Revealed by Expression of I
B Kinase-
Mutant*
§,
,
From the Health Effects Laboratory Division, NIOSH, Morgantown,
West Virginia 26505, the ¶ Department of Basic Pharmaceutical
Sciences, West Virginia University, Morgantown, West Virginia 26506, and the
Institute of Molecular Biology, University of Hong Kong,
Hong Kong, People's Republic of China
Received for publication, February 5, 2001, and in revised form, October 25, 2001
| |
ABSTRACT |
|---|
|
|
|---|
To delineate the molecular mechanisms of
NF- A wide range of signals, many of which are thought to be related
to cellular stress, induce expression of early response genes through
the NF- Increasing evidence indicates that NF- Apoptosis is a process in which cell death is initiated and completed
in an orderly fashion through the activation of various apoptotic
pathways (22, 23). However, in cases of severe injury, cells may
instead undergo necrosis, a passive death resulting in cellular lysis
(23). Most apoptotic cells are characterized by unique morphological
features, such as membrane blebbing, cell shrinking, cytosolic and
nuclear condensation, and breakdown of chromosomal DNA. In contrast,
cells dying by necrosis are characterized by cellular edema and loss of
cell membrane integrity. Depending on the involvement of caspases or
reactive oxygen species, cell death can be apoptotic, necrotic, or both
(24). In fact, under many circumstances, different death pathways can
co-exist in the same cell and are switched on by specific stimuli. A
number of studies have revealed that when a cell dies by a typical
apoptotic process, usually a late phase necrosis also occurs
(25-29).
Cr(VI) compounds, widely used in industry, have been shown to have
serious toxic and carcinogenic effects on humans. Although the
biochemical features of the signals that associate Cr(VI) with NF- Cells and Reagents--
The human bronchial epithelial cell
line, BEAS-2B, from American Type Culture Collection (ATCC, Manassas,
VA) was cultured in keratinocyte basal medium (Sigma) supplemented with
30 µg/ml bovine pituitary extract and 5 ng/ml human epidermal growth
factor. Mouse embryo fibroblasts (MEF) derived from wild-type mice and IKK Cell Transfection--
pCR-FLAG-IKK Electrophoretic Mobility Shift Assay (EMSA)--
For nuclear
protein extraction, cells were harvested and resuspended in hypotonic
buffer A (10 mM HEPES (pH 7.6), 10 mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride) as previously described
(35). Briefly, cells were incubated in buffer A for 10 min on ice and
then vortexed for 10 s. Nuclei were pelleted by centrifugation at
12,000 × g for 20 s and were resuspended in
buffer C (20 mM HEPES (pH 7.6), 25% glycerol, 0.4 M NaCl, 1 mM EDTA, 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride) for 30 min on ice. The
supernatants containing nuclear proteins were collected after
centrifugation at 12,000 × g for 2 min and stored at
Kinase Activity Assay--
The IKK activity assay was performed
by the method reported by Geleziunas et al. (36) with minor
modifications. Briefly, transfected BEAS-2B cells, seeded at a
concentration of 5 × 106 cells/ml and cultured for 2 days, were treated with indicated agents and lysed in a lysis buffer
containing 1% Nonidet P-40, 250 mM NaCl, 50 mM
HEPES (pH 7.4), 1 mM EDTA, 0.5 mM
phenylmethylsulfonyl fluoride, 1 mM DTT, 10 µg/ml
aprotinin, and 10 µg/ml leupeptin. After centrifugation of the lysate
at 16,000 × g for 20 min at 4 °C, the supernatant
was incubated with anti-IKK Clonogenic Survival Assay and Cell Death
Assay--
Logarithmically growing cells stably transfected with
indicated expressing vectors were harvested by typsinization. Cell
suspensions were seeded into six-well tissue culture plates with a
concentration of 103 cells/well. After allowing cells to
adhere for 12 h, the cells were treated with various
concentrations of Cr(VI) for an additional 12 h. After the
treatment, cells were washed and incubated for 1 week in tissue culture
medium containing 5% fetal bovine serum. At the end of culture, the
cell colonies were washed and fixed by the addition of water/methanol
(1:1, v/v) containing crystal violet (1 mg/ml) and counted under a
microscope. The clonogenic survival rate was calculated based on the
number of colonies that grew and the number of cells plated into each
well. For the analysis of cell death, stably co-transfected cells with
the pEGFPluc and/or other indicated vectors were cultured in six-well
tissue culture plates for 48 h before the experiments. The
percentage of green cells was determined by fluorescence microscopy.
Five independent counts in each experiment were used to determine a
mean and S.D.
Genefilter Microarray and RT-PCR--
The Genefilter membrane
(gf2l1) from Research Genetics (Huntsville, AL), which covers
3,965 genes, was used for mRNA expression profiling following the
manufacturer's instructions. Briefly, 1 µg of total RNA extracted
from transfected cells was incubated with 2 µg of oligo(dT); 1.5 µl
of reverse transcriptase; 20 mM dATP, dGTP, and dTTP; and
100 µCi of [32P]dCTP in 30 µl of
diethylpyrocarbonate-treated water for 90 min at 37 °C. After
purification through a Bio-Spin 6 chromatography column, labeled probe
was mixed with prehybridization solution and incubated with Genefilter
membranes overnight at 42 °C. To minimize possible variations among
individual membranes, the same membrane was stripped and rehybridized
with a second probe after the first round of hybridization. To verify
the microarray data, some of the differentially regulated genes in the
transfected cells, wild-type or IKK Western Blotting--
Whole cell extracts were mixed with 3×
SDS-PAGE sample buffer and then subjected to SDS-PAGE in 10 or 16%
gels. The resolved proteins were transferred to a nitrocellulose
membrane. Western blotting was performed using antibodies against
IKK Inhibition of IKK
To verify that the inhibition of NF- IKK
The role of IKK
To further assess the cytotoxic effect of Cr(VI) on the cells in which
NF- Spontaneous Cleavage of Bcl-xl in IKK
To rule out the possibility that above observations are artifacts due
to overexpression of IKK Decreased cIAP Expression in IKK
To verify the difference of gene expression observed by microarray
analysis between IKK Cr(VI)-induced Cell Death Can Be Partially Inhibited by Exogenous
cIAP1--
To determine whether Cr(VI)-induced necrotic-like cell
death of IKK
The possible protective role of cIAP1 on Cr(VI)-induced cytotoxicity
was also determined by cell viability analysis of IKK The results presented here provide evidence for a novel function
of NF- While the mechanism by which NF-
B-mediated regulation of chromium(VI)-induced cell death, the
signaling pathway leading to the activation of NF-
B was interrupted
by stable transfection of a kinase-mutated form of I
B kinase
(IKK
-KM). Here we demonstrate a novel role for the NF-
B
transcription factor in inhibiting chromium(VI)-induced cell death.
Inhibition of NF-
B by IKK
-KM or IKK
gene deficiency resulted
in a spontaneous cleavage of Bcl-xl antiapoptotic protein due to the
elevated caspase-3 activity. DNA microarray assay suggested a decreased
expression of genes encoding antiapoptotic proteins, cIAP1 and cIAP2,
in the cells overexpressing IKK
-KM. Chromium(VI) treatment of
these NF-
B-inhibited cells induced necrotic-like cell death. Such
chromium(VI)-induced cell killing could be partially inhibited by
expression of exogenous cIAP1, an inhibitor of caspases, indicating
that caspases along with others may be involved in chromium(VI)-induced
cell death. These results suggest that NF-
B is essential for
inhibiting toxic metal-induced cytotoxicity. Such inhibition may
involve up-regulation of the expression of anti-death proteins
including cIAP1 that prevents spontaneous caspase activation and
subsequent cleavage of Bcl-xl protein.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
B family of transcription factors (1-4). In resting cells,
NF-
B is retained in cytoplasm in its inactive form by interaction
with one of a number of inhibitory molecules including I
B
,
I
B
, I
B
, p105, and p100. Activation of the NF-
B signaling cascade results in a complete degradation of I
B or carboxyl-terminal partial degradation of the p105 and p100 precursors, allowing nuclear
translocation of the NF-
B complexes. Activated NF-
B binds to
specific DNA sequences in target genes, designated as
B elements,
and regulates transcription of genes mediating inflammation, carcinogenesis, and pro- or antiapoptotic reactions. I
B
is the most abundant inhibitory protein for NF-
B (5). The mechanisms of
signal-induced I
B
degradation involve phosphorylation of two
serine residues, Ser32 and Ser36. This
phosphorylation leads to polyubiquitination of two specific lysines on
I
B
(Lys21 and Lys22) by an SCF-
-TrCP
complex and its degradation by the 26 S proteasome (6). The
phosphorylation is accomplished by a specific I
B kinase
(IKK)1 complex containing two
catalytic subunits, IKK
and IKK
, and a structural component named
NEMO/IKK
/IKKAP (3, 5). IKK
and IKK
share 50% sequence
homology. Both proteins contain an amino-terminal kinase domain, a
carboxyl-terminal region with a leucine zipper, and a helix-loop-helix
domain. In vitro and in vivo studies indicate
that both IKK
and IKK
are capable of phosphorylating I
B
on
Ser32 and Ser36, but IKK
is more potent in
I
B
phosphorylation induced by proinflammatory stimuli. Recent
studies by several groups indicate the existence of an additional
IKK-like kinase complex in T cells, named IKKi/
, which shares 27%
homology with IKK
and IKK
and possibly mediates NF-
B-activating kinase signaling and phorbol 12-myristate
13-acetate/protein kinase C
-induced Ser36
phosphorylation of I
B
and thus NF-
B activation (7-11).
B is either a pro- or
antiapoptotic transcription factor regulating a variety of
apoptotic responses (12). NF-
B is activated in response to
several proapoptotic stimuli including oxidative stress, cytotoxic
drugs, and ionizing radiation (13, 14). Consistent with this notion,
the gene encoding Fas ligand (FasL) has been shown to be
transcriptionally regulated by NF-
B in response to T-cell activation
signals and to chemotherapeutic agents (15, 16). The evidence that
NF-
B is also an antiapoptotic transcription factor is mainly
provided by gene knockout studies of NF-
B family members and IKK
kinase subunits (17-19). RelA (p65)-deficient mice die during
embryonic development through apoptosis of hepatocytes (17). IKK
gene knockout mice die as embryos and show massive liver cell
apoptosis, a response similar to that of NF-
B p65 gene knockout mice
(19). Male mice with an inactivated X-linked gene encoding IKK
/NEMO, an essential modulator of the IKK complex for NF-
B activation, die
at midgestation due to a massive cortical and medulla lymphocyte apoptosis in the thymus in addition to degeneration of the liver (20,
21). Thus, in certain situations, NF-
B is proapoptotic, but in
alternative situations and cell types, NF-
B inhibits apoptosis and contributes to cell proliferation or transformation. Therefore, cell type and inducing stimuli appear to determine whether NF-
B is a
causal or secondary event in apoptosis.
B
activation and cell death have so far remained unclear, both reactive
oxygen species (ROS)-dependent and ROS-independent mechanisms have been proposed (30-32). The importance of NF-
B as an
antiapoptotic factor is evident mainly from the studies of gene
knockout mice and the apoptotic pathways of tumor necrosis factor
signaling (17-19, 33). Much less is known concerning the role of
NF-
B in Cr(VI)-induced cell death. The objective of the present
investigation was to clarify the involvement of NF-
B in
Cr(VI)-induced cell death and to determine if NF-
B plays a
protective or promoting role in cell death triggered by Cr(VI).
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
gene knockout mice were a gift from Dr. Michael Karin
(University of California, San Diego, La Jolla, CA) and cultured in
Dulbecco's modified Eagle's medium (Invitrogen) supplemented
with 10% fetal bovine serum. Cr(VI) was purchased from Aldrich. The
luciferase assay kit was from Promega (Madison, WI). All antibodies
against NF-
B family members, IKK
, procaspase-3, Bcl-xl, and Myc
tag were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) or
Upstate Biotechnology, Inc. (Lake Placid, NY). Anti-FLAG monoclonal
antibody was from Sigma. ECL Western blotting detection reagents were
from Amersham Biosciences.
and pCR-FLAG-IKK
-KM
(K44A) were gifts from Dr. Hiroyasu Nakano (Juntendo University,
Japan). pcDNA3-myc-IAP1 was provided by Dr. John C. Reed (The
Burnham Institute, La Jolla, CA). pEGFPluc vector was purchased from
CLONTECH Laboratories, Inc. (Palo Alto, CA).
BEAS-2B cells were plated in six-well tissue culture plates at 5 × 105 cells/well for 2 days. The cells were transfected
with a control vector (pCR3) or indicated expression vectors along with
a 2×
B-dependent luciferase reporter construct using
LipofectAMINE (Invitrogen) as previously described (34). Single clones
of BEAS-2B cells, stably transfected with the control vector (pCR3), wild-type IKK
, or IKK
-KM, and luciferase reporter genes, were isolated in 700 µg/ml G418 for 3 weeks and tested by Western blotting and luciferase activity assay for expression of the transfected genes.
Stably transfected cells were maintained in regular culture medium supplemented with 200 µg/ml G418. To minimize possible clone variations during the course of selection, several independently derived cell lines expressing each transfected vector with similar expression levels were pooled together for the experiments described below.
70 °C. For EMSA, 4 µg of nuclear extract were mixed with the
32P-labeled double-stranded oligonucleotide containing a
B sequence (5'-CAACGGCAGGGGAATTCCCCTCTCCTT-3'). The
reaction solution was incubated at room temperature for 30 min and
electrophoresed on a native 5% polyacrylamide gel in 0.25× TBE buffer
for 2-3 h. The DNA-binding proteins were visualized by autoradiography.
antibody H-470 or anti-FLAG antibody
with rotation for 4 h at 4 °C, followed by the addition of 20 µl of Protein A-agarose and incubation at 4 °C for an additional
2 h. The immunoprecipitate was collected by centrifugation at
2,000 × g and washed three times with lysis buffer and
two times with kinase buffer containing 20 mM HEPES (pH
7.4), 20 mM
-glycerophosphate, 1 mM
MnCl2, 5 mM MgCl2, 2 mM
NaF, and 1 mM DTT. To monitor the kinase reaction, the
immunoprecipitate was incubated in 20 µl of kinase buffer
supplemented with 5 µCi of [
-32P]ATP and 1 µg of
GST-I
B
(1-54) (CLONTECH, Palo Alto, CA) for 30 min at 30 °C. The reaction was stopped by the addition of SDS sample buffer. The samples were separated by SDS-polyacrylamide gel
electrophoresis (SDS-PAGE), which was then transferred onto a
nitrocellulose membrane and subjected to autoradiography.

/
MEF, were
analyzed by RT-PCR. The primers used for RT-PCR were designed by using
Primer3 software (available on the World Wide Web at
www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi) and indicated in
Table I.
Sequences of PCR primers used for the RT-PCR experiments
, FLAG, Myc tag, Bcl-xl, caspase-3, and anti-rabbit
IgG-horseradish peroxidase conjugates.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
Blocks NF-
B Activation--
IKK
has
been considered as the major I
B
kinase in response to a variety
of stimuli (3, 5). To determine whether overexpression of a
kinase-mutated form of IKK
(IKK
-KM) can lead to inhibition of
NF-
B, we characterized BEAS-2B cell clones stably expressing either
wild-type IKK
or IKK
-KM along with an
NF-
B-dependent luciferase reporter construct. BEAS-2B
cells transfected with the empty vector pCR3 were employed as a
control. To exclude the potential problem associated with
overexpression, we selected clones with a range of expression of the
exogenous proteins relative to the endogenous IKK
and identified
clones with comparable levels of expression of wild-type IKK
and
IKK
-KM. We first confirmed the previously observed inhibition of
NF-
B in the cells expressing IKK
-KM (37). The nuclear proteins
were prepared from the transfected clones in the absence or presence of
various doses of Cr(VI) for 1 h and subjected to EMSA. Fig.
1A shows that NF-
B DNA
binding activity in the cells transfected with a control vector or
wild-type IKK
could be induced by Cr(VI) in a
dose-dependent manner. In contrast, no or very marginal
induction of NF-
B DNA binding activity by Cr(VI) could be observed
in the cells transfected with IKK
-KM (Fig. 1A,
lanes 6-10, upper panel).
The same nuclear extracts were also analyzed for the Sp1 DNA binding
activity. As shown in Fig. 1A, overexpression of IKK
-KM
did not alter the Sp1 DNA binding activity in the cellular response to
Cr(VI) (Fig. 1A, bottom panel).

View larger version (70K):
[in a new window]
Fig. 1.
Inhibited activation of
NF-
B in the cells transfected with
IKK
-KM. A, cells were
transfected with the indicated vectors and treated with different doses
of Cr(VI) for 1 h. NF-
B (top panel) or
Sp1 (bottom panel) DNA binding activity was
determined by EMSA. N.S., nonspecific binding. B,
transfected cells treated with 5 or 10 µM Cr(VI) for 40 min. In vitro IKK kinase activity analysis and
immunoblotting using anti-FLAG antibody and anti-IKK
antibody were
performed as described under "Materials and Methods."
B was a result of the functional
disruption of IKK in cells expressing IKK
-KM, we examined IKK kinase
activity in these cells in the absence or presence of Cr(VI). Cell
extracts prepared at a 40-min time point after treatment with Cr(VI)
were immunoprecipitated using IKK
antiserum and subjected to an
immune complex kinase assay using GST-I
B
(amino acids 1-54) as
the substrate. As depicted in Fig. 1B, Cr(VI) stimulated IKK
kinase activity in the cells transfected with a control vector or
wild-type IKK
(Fig. 1B, lanes 1-3
and lanes 7-9, top panel).
Only marginal IKK kinase activity was induced by Cr(VI) in the cells
stably expressing IKK
-KM (Fig. 1B, lanes 4-6, top panel). Essentially equal
amounts of IKK
proteins were present in the extracts from the cells
transfected with vector, IKK
-KM, or IKK
as verified by immunoblot
using anti-FLAG and anti-IKK
antibodies (Fig. 1B,
middle and bottom panels). Since the
transfected IKK
and IKK
-KM were consistently of the expected size
in the immunoblot using anti-FLAG antibody (Fig. 1C,
third panel), it seemed unlikely that the
IKK
-KM coding region had undergone mutation or rearrangement during
plasmid amplification or integration into genomic DNA. Thus, these
results suggest that the IKK kinase activity is indeed inhibited in the
cells expressing a kinase-mutated form of IKK
, IKK
-KM.
Inhibition Enhances Cell Death--
Evidence that cells
lacking NF-
B activity undergo apoptosis suggests that NF-
B
activation provides protection against apoptotic signals (17). The
above data show that NF-
B activation in response to Cr(VI) is
defective in the cells expressing IKK
-KM. We next determined whether
NF-
B inhibition by expression of IKK
-KM sensitized cells to
apoptosis in response to Cr(VI). To our surprise, Cr(VI) (5 µM) treatment for 12 h induced a necrotic-like,
rather then apoptotic, cell death of IKK
-KM cells. Morphologic
analysis of phase-contrast images of cells indicates that only a few
control vector-transfected cells or wild-type IKK
-expressing cells
exhibited partial cell shrinkage and condensation after the treatment
with Cr(VI) (Fig. 2, F and
G). In contrast, after the same treatment, IKK
-KM-expressing cells manifested cell blebbing, swelling, and loss
of membrane integrity, characteristics similar to those seen in cells
undergoing necrosis (Fig. 2H).

View larger version (86K):
[in a new window]
Fig. 2.
Cr(VI)-induces necrotic-like cell death in
NF-
B-inhibited cells. Phase-contrast
morphologic analysis of the cells transfected with indicated vectors or
MEF derived from wild-type mice (WT) or IKK
gene knockout
mice (IKK
/
) in the absence (A-E) or
presence of 5 µM Cr(VI) (F-J) for 12 h.
and NF-
B in controlling Cr(VI)-induced
cytotoxicity was further investigated genetically using a knockout MEF
cell line lacking IKK
subunits. A dramatic loss of cell viability in
response to Cr(VI) was observed in IKK
/
MEF (Fig.
2J) but not in wild-type MEF (Fig. 2I). Thus,
these results excluded the potential artifacts associated with the use of dominant negative IKK
kinase mutant in overexpression experiments (Fig. 2H).
B was inhibited due to overexpression of IKK
-KM or deficiency
of the IKK
gene, IKK
-expressing cells, IKK
-KM-expressing cells, wild-type MEF, and IKK
/
MEF were treated with
increasing concentrations of Cr(VI). Cytotoxicity was determined by
both LDH release analysis and clonogenic survival assay. As indicated
in Fig. 3, A and B,
compared with their wild-type counterparts, a substantial increase of
LDH release was observed in IKK
-KM cells (Fig. 3A) and in
IKK
/
cells (Fig. 3B) in response to
various doses of Cr(VI). Consistent with this observation, the
clonogenic survival assay indicated that exposure to increasing amounts
of Cr(VI) inhibited clonogenic survival in IKK
-KM cells and
IKK
/
MEF more effectively than in the cells
expressing wild-type IKK
or wild-type MEF (Fig. 3C). Fig.
3D depicts a representative clonogenic survival
experiment.

View larger version (41K):
[in a new window]
Fig. 3.
Cr(VI) increases LDH release from and
inhibits clonogenic survival of IKK
-KM cells
and
IKK
/
cells. A, cells transfected with the indicated vectors
were treated with various doses of Cr(VI) for 12 h. LDH release
was determined as described under "Materials and Methods." Values
are means ± S.D. of five determinations. B, MEF
cells derived from wild-type or IKK
/
mice were
treated with Cr(VI) and analyzed for LDH release as in A. C, the effect of Cr(VI) on clonogenic survival was
determined in the cells transfected with the indicated vectors or the
cells with the indicated genetic background. Data indicate survival as
a percentage of untreated cells. Values are means ± S.D. of three
determinations. D, typical clonogenic survival
assay of cells expressing IKK
or IKK
-KM after the treatment of
Cr(VI) as described under "Materials and Methods."
-KM Cells or
IKK
/
Fibroblasts--
It has been demonstrated that
the bcl-x gene is a transcriptional target of NF-
B
in both mouse and human cells (35, 38). Enhanced NF-
B activity has
been correlated with the up-regulated expression of Bcl-xl, an
important antiapoptotic protein that can stabilize mitochondrial
membranes and prevent the release of cytochrome c and
apoptosis-inducing factor (39-41). A possible explanation for the
increased vulnerability of IKK
-KM-expressing cells in response to
Cr(VI) is that these cells may lack sufficient anti-death proteins,
such as Bcl-xl, due to the impairment of NF-
B signaling. Decreased
expression of Bcl-xl can cause either apoptosis due to the increase
of mitochondrial membrane permeability or necrosis due to the collapse
of fragile mitochondria (42). However, gene expression profiling showed
no difference of bcl-xl gene expression between IKK
and
IKK
-KM expressing cells (data not shown). Unexpectedly, spontaneous
cleavage of Bcl-xl protein was observed in IKK
-KM-expressing cells
but not in control vector- or wild-type IKK
-transfected cells (Fig.
4A, left
panel). A 17-kDa fragment occurred concomitant with a
disappearance of the 30-kDa intact Bcl-xl protein band in nonstimulated
or Cr(VI)-stimulated IKK
-KM-expressing cells. There are two
potential cleavage sites of caspase-3 (HLAD61/S and SSLD76/A) that are
located in the loop region between the BH4 and BH3 domains of the
Bcl-xl protein (43, 44). Cleavage of these sites by activated caspases
releases a C-terminal product that lacks the BH4 domain, an
antiapoptotic domain of Bcl-xl protein. The spontaneous cleavage of
Bcl-xl in IKK
-KM cells indicated possible activation of caspases in
these cells. Indeed, immunoblotting shows a basal activation of
caspase-3 as judged by the cleavage of the 32-kDa precursor caspase-3
with the appearance of a 12-kDa activated caspase-3 fragment (Fig. 4A, right panel). Cr(VI) treatment did
not further alter the cleavage of Bcl-xl and activation of caspase-3,
indicating that Cr(VI) itself has no effect on proteases responsible
for the cleavage of Bcl-xl or the activation of caspase-3.

View larger version (38K):
[in a new window]
Fig. 4.
Cleavage of Bcl-xl protein and activation of
caspase-3 in IKK
-KM cells or
IKK
/
MEF. A, total cellular proteins extracted from
transfected cells with indicated vectors and treated with 5 µM Cr(VI) for 12 h were subjected to immunoblotting
using antiserum against C-terminal Bcl-xl (left
panel) or caspase-3 (right panel). The
intact 30-kDa Bcl-xl protein band and the 32-kDa procaspase-3 are
indicated by arrows. The arrowheads indicate the
cleaved C-terminal 17-kDa Bcl-xl fragment and activated 12-kDa
caspase-3, respectively. The relative molecular masses are
indicated as kDa to the right of each panel.
N.S., nonspecific bands. B, wild-type
and IKK
/
MEF cultured in the absence
(lanes 1 and 3) or presence
(lanes 2 and 4) of 5 µM
Cr(VI) for 12 h. Total cellular proteins were extracted and
subjected to immunoblot using antibodies against IKK
, IKK
,
Bcl-xl, and caspase-3.
-KM, we next examined the status of Bcl-xl
proteins and caspase-3 in MEF cells derived from both wild-type mice
and IKK
gene knockout mice. As depicted in Fig. 4B,
IKK
protein is absent in IKK
-deficient MEF
(IKK
/
; Fig. 4B, top
panel). However, these cells express comparable levels of
IKK
as observed in wild-type cells (Fig. 4B, the second panel). The spontaneous cleavage of Bcl-xl protein and activation of
caspase-3 are evident in IKK
/
cells (Fig.
4B, third and bottom
panels, respectively).
-KM Cells--
The spontaneous
activation of caspase-3 in IKK
-KM cells implied an impaired
antiapoptotic function in these cells. It is known that NF-
B may
regulate the expression of several antiapoptotic genes, such as cIAP1
and cIAP2. The failure of IAP antibody to detect IAP proteins in our
system prompts us to analyze the basal gene expression profile of both
wild-type IKK
and IKK
-KM-expressing cells by DNA microarray. Both
wild-type IKK
- and IKK
-KM-expressing cells were cultured in
medium for 12 h. cDNA probes were generated from the RNAs of
both cell lines and used for sequential hybridization with the human
Genefilter gf2l1, which contains 3,965 sequence-verified known
human genes. The majority of these genes were expressed at similar
levels in cells stably expressing either wild-type IKK
or IKK
-KM.
In IKK
-KM cells, several genes encoding proteins involved in the
P450 function/cellular redox regulation, protein degradation, cell
cycle, and transforming growth factor-
signaling were up-regulated
by more than 2.5-fold in comparison with IKK
cells (Fig.
5). Thus, these data indicate that
NF-
B may negatively regulate the expression of these genes. At least
two recent reports also demonstrated that NF-
B suppressed the
expression of the P4501A1 (cyp1a1) gene (45) and a
proteasome C3 subunit gene (46). Under the basal condition, many of the
documented NF-
B target genes, such as cytokines and chemokines, were
not changed (data not shown). However, we did note a decreased
expression of both cIAP1 and cIAP2 genes in IKK
-KM cells. Both cIAP1
and cIAP2 have been originally identified as direct inhibitors for caspases, especially for caspase-3, caspase-7, and caspase-9 (47). In
addition, the expression of genes encoding transcription factor E2F5,
keratin 18, and an antioxidant protein, protein disulfide isomerase-related protein, is decreased in the IKK
-KM cells. Therefore, the observed spontaneous activation of caspase-3 in IKK
-KM cells may be explained as the lack of sufficient endogenous caspase inhibitors, such as cIAP1 and cIAP2.

View larger version (37K):
[in a new window]
Fig. 5.
Inhibition of IKK
decreases the expression of antiapoptotic genes encoding cIAP1
and cIAP2. A, cDNA microarray analysis of gene
expression was performed by using Genefilter membrane (gf211)
and [32P]dCTP-labeled cDNA probe synthesized from
poly(A)+ mRNA that was extracted from the
IKK
-KM-expressing cells and IKK
-expressing cells. The magnitude
of the changes reported was computed as -fold changes of the average
values over the two sets of comparisons. Only those genes with a more
than 2.5-fold change were shown. Filled bars
indicate those genes encoding products that participate in the P450
function or cellular redox regulation; dotted
bars indicate the genes involved in ubiquitin-proteasome
degradation pathways; hatched bars indicate those
genes encoding proteins participating in cell cycle regulation;
open bars indicate TGF
family genes;
cross-hatched bars to the left indicate the genes
with a decreased expression in IKK
-KM cells. B,
representative RT-PCR analysis confirming some of the genes showing
altered expression by the microarray in A. The primers and
RT-PCR conditions are shown in Table I. The bottom
panel shows the RT-PCR product of 7 S RNA to document an
equal amount of RNAs used in this assay.
- and IKK
-KM-expressing cells, we next
performed RT-PCR using equal amount of total RNAs from
IKK
-expressing cells, IKK
-KM-expressing cells, wild-type MEF, or
IKK
/
MEF. The results of the RT-PCR analysis
confirmed decreased expressions of cIAP1 and cIAP2 and increased
expression of endothelial nitric-oxide synthase and POH1 in IKK
-KM
cells (Fig. 5B). In fact, the cIAP1 expression appears to be
undetectable in the cells stably expressing IKK
-KM in this RT-PCR
analysis (Fig. 5B, lane 4 of the
cIAP1 panel). In addition, we also compared the
expression levels of endothelial nitric-oxide synthase, POH1, cIAP1,
and cIAP2 between wild-type MEF and IKK
/
MEF.
Similar to the BEAS-2B cells stably expressing IKK
-KM, the
IKK
/
MEF exhibited an increased expression of POH1
and decreased expression cIAP2 (Fig. 5B, lane
6). We failed to detect the expression of endothelial
nitric-oxide synthase and cIAP1 in both wild-type and
IKK
/
MEF. For unknown reasons, we also failed to
detect the expression of the XDH gene in both BEAS-2B
cells transfected with different vector and MEF with different genetic
backgrounds in several RT-PCR analyses (data not shown).
-KM cells was in fact due to the reduced expression of cIAP1 genes, we tested whether overexpression of cIAP1 was capable of
reducing Cr(VI)-induced cell death. The IKK
-KM cells were further
transfected with a control vector, pcDNA, or a vector expressing
Myc-tagged cIAP1 and cultured for 48 h. Cells were then left
untreated or treated with various concentrations of Cr(VI). After an
additional 12 h, the caspase-3 activation, Bcl-xl cleavage, and
LDH release were determined. As depicted in Fig. 6A, IKK
-KM cells
transfected with the control vector exhibited spontaneous activation of
caspase and Bcl-xl cleavage as judged by the disappearance of
procaspase-3 bands and intact Bcl-xl bands (Fig. 6A,
lanes 4-6, top and middle
panels). In contrast, transfection of Myc-tagged cIAP1
significantly blocked caspase-3 activation and Bcl-xl cleavage under
either basal or Cr(VI)-treated conditions (Fig. 6A,
lanes 1-3, top and middle
panels).

View larger version (29K):
[in a new window]
Fig. 6.
Exogenous cIAP1 inhibits spontaneous
activation of caspase-3 and cleavage of Bcl-xl. A,
cells stably expressing IKK
-KM were transiently transfected with a
Myc-tagged cIAP1 (lanes 1-3) or a control
vector, pcDNA (lanes 4-6). Approximately
48 h posttransfection, cells were treated with various doses of
Cr(VI) as indicated for an additional 12 h. Thereafter, extracts
were prepared and analyzed for caspase-3 activation (top
panel) and Bcl-xl cleavage (middle
panel). The expression of transfected Myc-tagged cIAP1 was
verified in the same extracts by immunoblotting using anti-Myc antibody
(bottom panel). B, IKK
-KM cells
were co-transfected with pEGFPluc (GFP) and Myc-tagged cIAP1
(IAP1) or a control vector (pcDNA) and
subjected to cell viability analysis following 5 µM
Cr(VI) treatment. Values are means ± S.D. of five
determinations.
-KM cells
co-transfected with pEGFPluc and Myc-tagged cIAP1 or pcDNA control
vector (Fig. 6B). While 5 µM Cr(VI)
substantially decreased the percentage of green cells of IKK
-KM
cells co-transfected with pEGFPluc and control vector, less effect of
Cr(VI) on the loss of percentage of green cells was observed in
IKK
-KM cells co-transfected with pEGFPluc and Myc-tagged cIAP1.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
B in inhibiting Cr(VI)-induced necrotic-like cell death. In
the cells stably expressing IKK
-KM, an essential component of
NF-
B signaling, IKK
, is defective (Fig. 1B). EMSA
indicates a pronounced decrease of NF-
B DNA binding activity in
these IKK
-KM expression cells in response to Cr(VI) (Fig.
1A). Cell morphologic analysis demonstrates that treatment
of the cells expressing IKK
-KM with Cr(VI) induced a necrotic-like
cell death (Fig. 2). Analysis of the protein expression levels for both
Bcl-xl and caspase-3 shows that IKK
-KM-expressing cells or IKK
gene knockout MEF exhibited spontaneous cleavage of Bcl-xl protein and
activation of caspase-3 (Fig. 4, A and B).
The gene expression profiling analysis reveals that inhibition
of IKK
to block NF-
B signaling decreased the expression of two
important antiapoptotic genes, cIAP1 and cIAP2. Transfection of the
cells expressing IKK
-KM with cIAP1 partially prevents caspase-3
activation and Bcl-xl cleavage (Fig. 6A) and protects the
cells from Cr(VI)-induced cytotoxicity (Fig. 6B).
B protects cells from death signals
remains to be further investigated, it may be related to its
transcriptional regulation on several antiapoptotic genes (33). The
observations presented in this paper support the notion that NF-
B
plays a pivotal role in the expression of both cIAP1 and cIAP2 genes.
These data also support a model for the consequent effects of NF-
B
inhibition on Cr(VI)-induced cell death (Fig. 7). The levels of cIAPs and Bcl-xl may
determine whether necrotic cell death or apoptosis ensues in the
cellular response to Cr(VI). In NF-
B-inhibited cells, such as the
expression of IKK
-KM and IKK
gene knockout, caspase-3 was
activated due to the reduced expression of cIAP1 and cIAP2. Activated
caspase-3 cleaves Bcl-xl, which not only weakens the protective
mechanism of Bcl-xl on the mitochondrial outer membrane but also
converts this antiapoptotic protein to a killer molecule (40, 41).
Under this predisposed condition, Cr(VI) treatment may result in
necrosis rather than apoptosis due to severe damage of mitochondria.
Severely damaged mitochondria release an excessive amount of cytochrome
c that interrupts electron transport in the inner membrane,
causing ATP depletion and consequently switching the cells from
apoptosis to necrosis. However, if the levels of cIAP1 and cIAP2 are
maintained by a normal NF-
B activation response, the cleavage of
Bcl-xl will be prevented by IAP-mediated inhibition of caspases (Fig. 6).

View larger version (33K):
[in a new window]
Fig. 7.
Possible mechanisms of Cr(VI)-induced
necrosis in NF-
B-inhibited cells.
Overexpression of a kinase-mutated IKK
(IKK
-KM) leads to the
inhibition of basal and subsequent inducible NF-
B activation,
resulting in decreased expression of cIAP1 and cIAP2. Caspase-3 is
spontaneously activated under this circumstance, which causes cleavage
of Bcl-xl protein. Bcl-xl cleavage not only weakens the protective
mechanism of Bcl-xl on mitochondrial outer membrane but also converts
this antiapoptotic protein to killer molecules of mitochondria.
Necrosis, rather then apoptosis, will occur upon persistent insults,
such as Cr(VI) or overwhelming ROS. Small up and
down arrows indicate increased and decreased
activities, respectively.
The protective effect of cIAP1 on Cr(VI)-induced death of IKK
-KM
cells is distinct from the previous reports indicating that peptidyl
caspase inhibitors potentiate tumor necrosis factor
- or
double-stranded RNA-induced cytotoxicity (48, 49). It should be noted
that there are several substantial differences between cIAPs and
peptidyl caspase inhibitors. In addition to their function as
endogenous inhibitors for caspases, cIAP1 and cIAP2 have recently been
shown to regulate several signal transduction pathways leading to the
activation of NF-
B and c-Jun N-terminal kinase (50, 51) and act as
ubiquitin ligases modulating protein degradation (52, 53). Thus, the
observed protection of cIAP1 from Cr(VI)-induced killing of IKK
-KM
cells might not only be the result of inhibition of caspases but
also the result of regulation of intracellular signal transduction.
It has been proposed that Cr(VI)-induced cellular responses are both
ROS-dependent and ROS-independent. A limited amount of ROS
can be buffered in cells by glutathione and thioredoxin (54, 55). This
raises the possibility that the increased vulnerability of
IKK
-KM-expressing cells to Cr(VI) may be partially due to a reduced
generation of oxidative buffering molecules. Indeed, the gene
expression profiling study showed that the lowest expressed gene in
IKK
-KM cells, compared with that in IKK
cells, is the gene
encoding protein-disulfide isomerase-related protein (Fig. 5), an
important member of the thioredoxin superfamily participating in redox
regulation (55). Lowered oxidative buffering could lead to oxidative
stress. Under this circumstance, the mitochondrial respiratory chain
would be easily disrupted. The cells would undergo necrosis rather than
apoptosis due to the depressed activation of caspases by Cr(VI) or ROS.
It has been demonstrated that activation of caspases requires ATP and
reduction of cysteine in the essential active center of caspases (24).
To support this, combined treatment of cells with cIAP1 and
N-acetyl-L-cysteine to elevate
intracellular thio-containing molecules, such as GSH, partially
protected IKK
-KM cells from Cr(VI)-induced
killing.2
In conclusion, we have demonstrated a novel function of NF-
B in
inhibiting Cr(VI)-induced cell death. The levels of cIAPs that are
transcriptionally regulated by NF-
B are critical in determining the
activation and activity of caspases and the integrity of the Bcl-xl
protein. Investigations are currently under way to address whether
other oxidative stress inducers, such as H2O2 and nitric oxide, exhibit a similar effect on the cells where NF-
B was specifically inhibited by different approaches
(e.g. gene knockout for IKK
or p65, transfection of
degradation-resistant I
B
, or delivery of peptidyl inhibitors for
the IKK complex).
| |
ACKNOWLEDGEMENTS |
|---|
We are grateful to Drs. Michael Karin and
Zhi-Wei Li (University of California, San Diego, La Jolla) for the gift
of wild type and IKK
gene knockout mouse embryo fibroblasts; to Dr.
Hiroyasu Nakano (Juntendo University, Tokyo, Japan) for providing the
pCR-FLAG-IKK
- and pCR-FLAG-IKK
-KM (K44A)-expressing vectors; to
Dr. John C. Reed at The Burnham Institute (La Jolla, CA) for the
c-Myc-cIAP1 expression vector; to Dr. Jacques Corbeil, Director of the
Center for AIDS Research Genomics Core (University of California at San Diego) for help with the Genefilter Microarray analysis; to Dr. Murali Rao (NIOSH) for a critical review of the manuscript; and to Dr.
LaCasse (University of Ottawa) for correcting IAP nomenclature.
| |
FOOTNOTES |
|---|
* This study was supported in part under the Interagency Agreement (98-18-00 m2) between the Occupational Safety and Health Administration and NIOSH.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Supported by a Career Development Award under a cooperative
agreement from the Centers for Disease Control and Prevention through
the Association of Teachers of Preventive Medicine.
§ To whom correspondence and reprint requests may be addressed: PPRB of NIOSH, 1095 Willowdale Rd., Morgantown, WV 26505. Tel.: 304-285-6021/6158; Fax: 304-285-5938; E-mail: lfd3@cdc.gov.
** To whom correspondence and reprint requests may be addressed: PPRB of NIOSH, 1095 Willowdale Rd., Morgantown, WV 26505. Tel.: 304-285-6021/6158; Fax: 304-285-5938; E-mail: xshi@cdc.gov.
Published, JBC Papers in Press, November 28, 2001, DOI 10.1074/jbc.M101089200
2 F. Chen, J. Bower, S. S. Leonard, M. Ding, Y. Lu, Y. Rojanasakul, H. Kung, V. Vallyathan, V. Castranova, and X. Shi, unpublished observation.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
IKK, I
B
kinases;
ROS, reactive oxygen species;
cIAP, cellular inhibitor of
apoptosis;
MEF, mouse embryo fibroblast(s);
DTT, dithiothreitol;
RT-PCR, reverse transcriptase-polymerase chain reaction;
LDH, lactate
dehydrogenase.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Baldwin, A. S., Jr. (1996) Annu. Rev. Immunol. 14, 649-683[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Karin, M. (1998) Cancer J. Sci. Am. 4 Suppl. 1, 92-99 |
| 3. | Karin, M., and Delhase, M. (2000) Semin. Immunol. 12, 85-98[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
Aggarwal, B. B.
(2000)
Ann. Rheum. Dis.
59 Suppl. 1,
i6-i16 |
| 5. | Israel, A. (2000) Trends Cell Biol. 10, 129-133[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Tan, P., Fuchs, S. Y., Chen, A., Wu, K., Gomez, C., Ronai, Z., and Pan, Z. Q. (1999) Mol. Cell 3, 527-533[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Peters, R. T., Liao, S. M., and Maniatis, T. (2000) Mol. Cell 5, 513-522[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Shimada, T.,
Kawai, T.,
Takeda, K.,
Matsumoto, M.,
Inoue, J.,
Tatsumi, Y.,
Kanamaru, A.,
and Akira, S.
(1999)
Int. Immunol.
11,
1357-1362 |
| 9. |
Takeda, K.,
Takeuchi, O.,
Tsujimura, T.,
Itami, S.,
Adachi, O.,
Kawai, T.,
Sanjo, H.,
Yoshikawa, K.,
Terada, N.,
and Akira, S.
(1999)
Science
284,
313-316 |
| 10. | Tojima, Y., Fujimoto, A., Delhase, M., Chen, Y., Hatakeyama, S., Nakayama, K., Kaneko, Y., Nimura, Y., Motoyama, N., Ikeda, K., Karin, M., and Nakanishi, M. (2000) Nature 404, 778-782[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Pomerantz, J. L., and Baltimore, D. (1999) EMBO J. 18, 6694-6704[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Aggarwal, B. B. (2000) Biochem. Pharmacol. 60, 1033-1039[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Schreck, R.,
Meier, B.,
Mannel, D. N.,
Droge, W.,
and Baeuerle, P. A.
(1992)
J. Exp. Med.
175,
1181-1194 |
| 14. | Pahl, H. L. (1999) Oncogene 18, 6853-6866[CrossRef][Medline] [Order article via Infotrieve] |
| 15. |
Kasibhatla, S.,
Genestier, L.,
and Green, D. R.
(1999)
J. Biol. Chem.
274,
987-992 |
| 16. | Kasibhatla, S., Brunner, T., Genestier, L., Echeverri, F., Mahboubi, A., and Green, D. R. (1998) Mol. Cell 1, 543-551[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S., and Baltimore, D. (1995) Nature 376, 167-170[CrossRef][Medline] [Order article via Infotrieve] |
| 18. |
Hu, Y.,
Baud, V.,
Delhase, M.,
Zhang, P.,
Deerinck, T.,
Ellisman, M.,
Johnson, R.,
and Karin, M.
(1999)
Science
284,
316-320 |
| 19. |
Li, Q.,
Van Antwerp, D.,
Mercurio, F.,
Lee, K. F.,
and Verma, I. M.
(1999)
Science
284,
321-325 |
| 20. |
Rudolph, D.,
Yeh, W. C.,
Wakeham, A.,
Rudolph, B.,
Nallainathan, D.,
Potter, J.,
Elia, A. J.,
and Mak, T. W.
(2000)
Genes Dev.
14,
854-862 |
| 21. | Makris, C., Godfrey, V. L., Krahn-Senftleben, G., Takahashi, T., Roberts, J. L., Schwarz, T., Feng, L., Johnson, R. S., and Karin, M. (2000) Mol. Cell 5, 969-979[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Green, D. R. (2000) Cell 102, 1-4[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Green, D. R., and Beere, H. M. (2000) Nature 405, 28-29[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Fiers, W., Beyaert, R., Declercq, W., and Vandenabeele, P. (1999) Oncogene 18, 7719-7730[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Dive, C., Gregory, C. D., Phipps, D. J., Evans, D. L., Milner, A. E., and Wyllie, A. H. (1992) Biochim. Biophys. Acta 1133, 275-285[Medline] [Order article via Infotrieve] |
| 26. | Geier, A., Weiss, C., Beery, R., Haimsohn, M., Hemi, R., Malik, Z., and Karasik, A. (1995) J. Cell. Physiol. 163, 570-576[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Chautan, M., Chazal, G., Cecconi, F., Gruss, P., and Golstein, P. (1999) Curr. Biol. 9, 967-970[CrossRef][Medline] [Order article via Infotrieve] |
| 28. |
Eguchi, Y.,
Shimizu, S.,
and Tsujimoto, Y.
(1997)
Cancer Res.
57,
1835-1840 |
| 29. | Shinoura, N., Yoshida, Y., Asai, A., Kirino, T., and Hamada, H. (1999) Oncogene 18, 5703-5713[CrossRef][Medline] [Order article via Infotrieve] |
| 30. |
Shumilla, J. A.,
Broderick, R. J.,
Wang, Y.,
and Barchowsky, A.
(1999)
J. Biol. Chem.
274,
36207-36212 |
| 31. | Chen, F., Ye, J., Zhang, X., Rojanasakul, Y., and Shi, X. (1997) Arch. Biochem. Biophys. 338, 165-172[CrossRef][Medline] [Order article via Infotrieve] |
| 32. | Shi, X., Chiu, A., Chen, C. T., Halliwell, B., Castranova, V., and Vallyathan, V. (1999) J. Toxicol. Environ. Health B Crit. Rev. 2, 87-104[CrossR |